Qiagen (QGEN) Aktienübersicht
Qiagen N.V. bietet Sample-to-Insight-Lösungen an, die biologische Proben weltweit in molekulare Erkenntnisse umwandeln. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 4/6 |
| Künftiges Wachstum | 1/6 |
| Vergangene Leistung | 4/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 2/6 |
QGEN Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Qiagen N.V. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$37.75 |
| 52-Wochen-Hoch | US$57.82 |
| 52-Wochen-Tief | US$32.53 |
| Beta | 0.66 |
| 1 Monat Veränderung | 14.26% |
| 3 Monate Veränderung | -8.40% |
| 1 Jahr Veränderung | -22.41% |
| 3 Jahre Veränderung | -26.84% |
| 5 Jahre Veränderung | -29.08% |
| Veränderung seit IPO | 1,622.59% |
Aktuelle Nachrichten und Updates
QGEN: Expect Balance Sheet Strength To Support Oncology And Diagnostics Expansion Beyond Current Headwinds
Qiagen's updated analyst price target has been reduced by about $9.70. This reflects analysts' lower growth and profitability assumptions after recent cuts across the Street tied to softer QuantiFERON trends and a rebased full year outlook.
Latent TB Testing Expansion And Automation Will Support Stronger Long Term Prospects
Catalysts About Qiagen Qiagen provides molecular diagnostics, sample preparation and bioinformatics tools used in clinical testing and research. What are the underlying business or industry changes driving this perspective?Recent updates
QGEN: Expect Balance Sheet Strength To Support Oncology And Diagnostics Expansion Beyond Current Headwinds
Qiagen's updated analyst price target has been reduced by about $9.70. This reflects analysts' lower growth and profitability assumptions after recent cuts across the Street tied to softer QuantiFERON trends and a rebased full year outlook.Latent TB Testing Expansion And Automation Will Support Stronger Long Term Prospects
Catalysts About Qiagen Qiagen provides molecular diagnostics, sample preparation and bioinformatics tools used in clinical testing and research. What are the underlying business or industry changes driving this perspective?
Latent Tuberculosis And Research Pressures Will Constrain Progress Yet Long-Term Prospects Remain Intact
Catalysts About Qiagen Qiagen provides sample preparation, diagnostic testing and bioinformatics tools for molecular and clinical laboratories. What are the underlying business or industry changes driving this perspective?QGEN: Expect Balance Sheet Strength To Support Oncology And Diagnostic Platform Expansion
Qiagen's analyst price target has been adjusted modestly lower to $53.53 from $55.46 as analysts factor in a slightly higher discount rate, a marginally different profit margin outlook, and recent target cuts and rating changes across major banks, alongside some upward revisions earlier in the period. Analyst Commentary Recent research shows a mix of optimism and caution around Qiagen, with several firms adjusting price targets in both directions and a few making rating changes.QGEN: I Expect Balance Sheet Strength To Drive Future Shareholder Returns
Qiagen's analyst price target is updated to $55.46. The modest change reflects mixed but generally constructive research commentary that cites an undemanding valuation, a robust balance sheet, and steady recent shareholder returns as key supports.QGEN: Possible Sale Prospects Are Expected To Drive Future Returns
The analyst price target for Qiagen has been nudged higher to $55.46 from $55.23, as analysts cite an undemanding valuation, a robust balance sheet, and a track record of average annual shareholder returns of 13% as key supports for the updated view. Analyst Commentary Recent research on Qiagen presents a mix of optimism and caution, with several firms adjusting ratings and price targets while focusing on valuation, balance sheet strength, and execution risk.QGEN: Possible Sale And Margin Upside Are Expected To Drive Future Returns
The Analyst Price Target on Qiagen has increased by $2, with analysts citing improved profit margin assumptions and a slightly lower future P/E multiple, while they refine discount rate and revenue growth inputs. Analyst Commentary Bullish and bearish analysts are split on Qiagen, with several firms lifting price targets while others trim estimates or ratings.QGEN: Possible Sale And Fresh Takeover Interest Will Drive Future Upside
Analysts have raised their blended price target for Qiagen by about $0.63 to $55.23. This reflects updated views on slightly different revenue growth, profit margin and future P/E assumptions after a mix of recent target increases and reductions across the Street.QGEN: Fairly Valued Outlook Will Hinge On Possible Sale And Execution Risks
Qiagen's analyst price target has edged up by about $1 to roughly $55, as analysts factor in slightly higher fair value and profit margin assumptions, along with a modest adjustment to growth expectations and P/E multiples. Analyst Commentary Recent Street research on Qiagen has been active, with several firms adjusting price targets in both directions and a few issuing downgrades.QGEN: Fairly Valued Outlook Will Depend On Possible Sale And Leadership Transition
Analysts have slightly raised their Qiagen price target to about $53.32 from $53.23, reflecting small tweaks to revenue growth, discount rate, profit margin, and future P/E assumptions following recent downgrades in Street research. Analyst Commentary Bullish Takeaways Bullish analysts see the updated price target of about US$53.32 as still supported by long term earnings potential, even after recent revisions to revenue growth and profit margin assumptions.Qiagen: Takeover Optionality With A High-Quality Consumables Platform
Summary QGEN is a consumable molecular diagnostics and life-science tools platform. They offer QuantiFERON, QIAstat-Dx, QIAcuity dPCR, and QDI bioinformatics. Recently, there’s renewed takeover speculation after reports that show they’re weighing strategic options. QGEN’s potential fits include Danaher or Agilent, with Thermo Fisher less likely after the 2020 deal talks failed. QGEN’s portfolio with Parse Biosciences adds single-cell sequencing scale, while 2026 automation launches would further deepen its differentiated workflow. I think QGEN now makes much more sense given the renewed M&A interest. But if deal talks fail or rumors cool, shares could de-rate, so my “Buy” rating is explicitly speculative. Read the full article on Seeking AlphaQGEN: Fairly Valued Outlook Will Rely On Leadership Transition And Acquisitions
Narrative Update on Qiagen Analysts have lifted their Qiagen fair value estimate from approximately €50.43 to about €53.23, citing updated assumptions around revenue growth, profit margins and the P/E multiple applied to future earnings. What's in the News Qiagen plans a stock split or significant stock dividend with a 1 to 1.05263 ratio effective January 8, 2026, which adjusts the number of shares while keeping overall value aligned with the split terms (Key Developments).An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 21% Undervalued
Key Insights The projected fair value for Qiagen is US$59.66 based on 2 Stage Free Cash Flow to Equity Qiagen is...QGEN: Stable End Markets Will Support Gradual Sentiment Recovery Ahead
Analysts have trimmed their price target on Qiagen slightly, with a modest fair value reduction of about $0.36 per share. They cite still stable end markets, expectations for gradual improvement ahead, and a view that investment sentiment and valuations have largely bottomed.QGEN: Gradual Improvement Ahead As End Markets Remain Stable And Sentiment Bottoms
Analysts have modestly lowered their price target for Qiagen from $55 to $53 per share, citing stable end markets and expectations of gradual improvement ahead. Analyst Commentary Analysts have provided a balanced view of Qiagen's current outlook, highlighting both opportunities and ongoing challenges as the company navigates a gradually improving market environment.QGEN: Improving Sentiment And Stable Markets Will Set Stage For Future Upside
Analysts have slightly lowered their price target for Qiagen, reducing it by approximately $0.86 to reflect stable end markets. They also acknowledge that improvement is expected as investment sentiment stabilizes.Earnings Beat: Qiagen N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Shareholders might have noticed that Qiagen N.V. ( NYSE:QGEN ) filed its quarterly result this time last week. The...QGEN: Future Results Will Depend On Automation And Gradual Sentiment Recovery
Analysts have slightly lowered their price target for Qiagen from $55 to $53, citing stable end markets and anticipated gradual improvements in investment sentiment. Analyst Commentary Recent analyst updates highlight a nuanced outlook for Qiagen, with attention drawn to both its strengths and areas of potential risk in the near term.Syndromic Diagnostics And Automation Will Shape Future Healthcare
Analysts have slightly lowered their price target for Qiagen, reflecting a small decrease from $51.79 to $51.64 per share. They cite ongoing stability in end markets and expectations for gradual valuation improvement.Syndromic Diagnostics And Automation Will Shape Future Healthcare
Analysts have slightly reduced their fair value and price targets for Qiagen, with the consensus moving from approximately $52.39 to $51.79. This change is attributed to stabilizing end markets and expectations of gradual improvement in industry conditions.Syndromic Diagnostics And Automation Will Shape Future Healthcare
Analysts remain cautiously optimistic on Qiagen, citing modest macroeconomic improvements and solid company execution despite persistent sector headwinds, resulting in an unchanged consensus price target of $52.39. Analyst Commentary Bullish analysts cite modest improvements in macroeconomic conditions, including easing tariff concerns, as supportive of Qiagen's shares.Qiagen's (NYSE:QGEN) Strong Earnings Are Of Good Quality
Qiagen N.V.'s ( NYSE:QGEN ) earnings announcement last week was disappointing for investors, despite the decent profit...Qiagen N.V. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
NYSE:QGEN 1 Year Share Price vs Fair Value Explore Qiagen's Fair Values from the Community and select yours The...Qiagen N.V.'s (NYSE:QGEN) Share Price Could Signal Some Risk
NYSE:QGEN 1 Year Share Price vs Fair Value Explore Qiagen's Fair Values from the Community and select yours When close...Qiagen N.V.: Some Clarity Needed Before Buying The Dip
Summary Qiagen N.V., a Netherlands-based medical diagnostics provider, faces market pressure due to some recent NIH funding concerns, despite strong financials and a diverse product portfolio. The company's free cash flow improved markedly in FY 2024, and the company announced a $300 million stock buyback program last month. An analysis around Qiagen N.V. follows in the paragraphs below. Read the full article on Seeking AlphaAktionärsrenditen
| QGEN | US Life Sciences | US Markt | |
|---|---|---|---|
| 7D | 5.8% | 3.4% | -3.3% |
| 1Y | -22.4% | 10.7% | 22.3% |
Rendite im Vergleich zur Industrie: QGEN unter dem Niveau der Branche US Life Sciences , die im vergangenen Jahr eine Rendite von 9.6% erzielte.
Rendite vs. Markt: QGEN hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 22.5 erzielte.
Preisvolatilität
| QGEN volatility | |
|---|---|
| QGEN Average Weekly Movement | 5.1% |
| Life Sciences Industry Average Movement | 9.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: QGEN hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: QGENDie wöchentliche Volatilität (5%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1984 | 5,500 | Thierry Bernard | www.qiagen.com |
Qiagen N.V. bietet Sample-to-Insight-Lösungen an, die biologische Proben weltweit in molekulare Erkenntnisse umwandeln. Das Unternehmen bietet Verbrauchsmaterialien für die Probentechnologie an, wie z. B. Kits zur Stabilisierung und Reinigung von Nukleinsäuren für Probenmaterialien, manuelle und automatisierte Verarbeitung für Genotypisierung, Genexpression und virale und bakterielle Analysen sowie Silikamembranen und magnetische Bead-Technologien; Verbrauchsmaterialien für die sekundäre Probentechnologie, einschließlich Kits und Komponenten für die Aufreinigung von Nukleinsäuren; und Instrumente für die Nukleinsäureaufreinigung, Qualitätskontrolle und Zubehör. Darüber hinaus bietet das Unternehmen Verbrauchsmaterialien für die Immunantwort, wie z. B. Interferon-Gamma-Freisetzungstests für Tuberkulosetests und Tests für Posttransplantationstests und die Überwachung der Viruslast; Verbrauchsmaterialien für die Onkologie und die sexuelle und reproduktive Gesundheit, einschließlich Tests für pränatale Tests und den Nachweis von sexuell übertragbaren Krankheiten und HPV; Tests für die Analyse genomischer Varianten; und Instrumente für die Analyse von Proben, einschließlich der einstufigen molekularen Analyse von schwer zu diagnostizierenden Syndromen und integrierten PCR-Tests.
Qiagen N.V.'s Grundlagenzusammenfassung
| QGEN grundlegende Statistiken | |
|---|---|
| Marktanteil | US$7.49b |
| Gewinn(TTM) | US$402.17m |
| Umsatz(TTM) | US$2.10b |
Ist QGEN zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| QGEN Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$2.10b |
| Kosten der Einnahmen | US$710.57m |
| Bruttogewinn | US$1.39b |
| Sonstige Ausgaben | US$986.13m |
| Gewinn | US$402.17m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 1.94 |
| Bruttomarge | 66.15% |
| Nettogewinnspanne | 19.16% |
| Schulden/Eigenkapital-Verhältnis | 50.0% |
Wie hat sich QGEN auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
Zahlt QGEN eine zuverlässige Dividende?
Siehe QGEN Dividendenhistorie und Benchmarks| Qiagen Dividendentermine | |
|---|---|
| Ex-Dividenden Datum | Jul 07 2026 |
| Datum der Dividendenzahlung | Jul 14 2026 |
| Tage bis Ex-Dividende | 27 days |
| Tage bis zum Datum der Dividendenzahlung | 34 days |
Zahlt QGEN eine zuverlässige Dividende?
Siehe QGEN Dividendenhistorie und BenchmarksUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/09 01:59 |
| Aktienkurs zum Tagesende | 2026/06/09 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Qiagen N.V. wird von 41 Analysten beobachtet. 15 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |
| Charles Butler | Barclays |